Literature DB >> 27231349

Loss of Mouse P2Y6 Nucleotide Receptor Is Associated with Physiological Macrocardia and Amplified Pathological Cardiac Hypertrophy.

Sophie Clouet1, Larissa Di Pietrantonio1, Evangelos-Panagiotis Daskalopoulos2, Hrag Esfahani3, Michael Horckmans1, Marion Vanorlé1, Anne Lemaire1, Jean-Luc Balligand3, Christophe Beauloye2, Jean-Marie Boeynaems4, Didier Communi5.   

Abstract

The study of the mechanisms leading to cardiac hypertrophy is essential to better understand cardiac development and regeneration. Pathological conditions such as ischemia or pressure overload can induce a release of extracellular nucleotides within the heart. We recently investigated the potential role of nucleotide P2Y receptors in cardiac development. We showed that adult P2Y4-null mice displayed microcardia resulting from defective cardiac angiogenesis. Here we show that loss of another P2Y subtype called P2Y6, a UDP receptor, was associated with a macrocardia phenotype and amplified pathological cardiac hypertrophy. Cardiomyocyte proliferation and size were increased in vivo in hearts of P2Y6-null neonates, resulting in enhanced postnatal heart growth. We then observed that loss of P2Y6 receptor enhanced pathological cardiac hypertrophy induced after isoproterenol injection. We identified an inhibitory effect of UDP on in vitro isoproterenol-induced cardiomyocyte hyperplasia and hypertrophy. The present study identifies mouse P2Y6 receptor as a regulator of cardiac development and cardiomyocyte function. P2Y6 receptor could constitute a therapeutic target to regulate cardiac hypertrophy.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  G protein-coupled receptor (GPCR); P2Y6 receptor; UDP; cardiac hypertrophy; cardiomyocyte; heart development; isoproterenol; nucleotide

Mesh:

Substances:

Year:  2016        PMID: 27231349      PMCID: PMC4957065          DOI: 10.1074/jbc.M115.684118

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  P2Y(4) nucleotide receptor: a novel actor in post-natal cardiac development.

Authors:  Michael Horckmans; Bernard Robaye; Elvira Léon-Gόmez; Nicolas Lantz; Philippe Unger; Frédérique Dol-Gleizes; Sophie Clouet; Dorothée Cammarata; Paul Schaeffer; Pierre Savi; Christian Gachet; Jean-Luc Balligand; Chantal Dessy; Jean-Marie Boeynaems; Didier Communi
Journal:  Angiogenesis       Date:  2012-03-22       Impact factor: 9.596

2.  Involvement of uracil nucleotides in protection of cardiomyocytes from hypoxic stress.

Authors:  Smadar Yitzhaki; Vladimir Shneyvays; Kenneth A Jacobson; Asher Shainberg
Journal:  Biochem Pharmacol       Date:  2005-04-15       Impact factor: 5.858

3.  Creatine kinase knockout mice show left ventricular hypertrophy and dilatation, but unaltered remodeling post-myocardial infarction.

Authors:  Matthias Nahrendorf; Matthias Spindler; Kai Hu; Lisa Bauer; Oliver Ritter; Peter Nordbeck; Thomas Quaschning; Karl-Heinz Hiller; Julie Wallis; Georg Ertl; Wolfgang R Bauer; Stefan Neubauer
Journal:  Cardiovasc Res       Date:  2005-02-01       Impact factor: 10.787

4.  Ventricular expression of natriuretic peptides in Npr1(-/-) mice with cardiac hypertrophy and fibrosis.

Authors:  Leigh J Ellmers; J W Knowles; H-S Kim; O Smithies; N Maeda; V A Cameron
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-08       Impact factor: 4.733

5.  Nebivolol prevents desensitization of β-adrenoceptor signaling and induction of cardiac hypertrophy in response to isoprenaline beyond β1-adrenoceptor blockage.

Authors:  Isil Ozakca; Ebru Arioglu-Inan; Hrag Esfahani; V Melih Altan; Jean-Luc Balligand; Gizem Kayki-Mutlu; A Tanju Ozcelikay
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-03-01       Impact factor: 4.733

6.  Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure.

Authors:  J W Adams; Y Sakata; M G Davis; V P Sah; Y Wang; S B Liggett; K R Chien; J H Brown; G W Dorn
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

7.  P2Y6 deficiency limits vascular inflammation and atherosclerosis in mice.

Authors:  Peter Stachon; Alexander Peikert; Nathaly Anto Michel; Sonja Hergeth; Timoteo Marchini; Dennis Wolf; Bianca Dufner; Natalie Hoppe; Cemil Korcan Ayata; Melanie Grimm; Sanja Cicko; Lisa Schulte; Jochen Reinöhl; Constantin von zur Muhlen; Christoph Bode; Marco Idzko; Andreas Zirlik
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-08-07       Impact factor: 8.311

8.  Gene deletion of P2Y4 receptor lowers exercise capacity and reduces myocardial hypertrophy with swimming exercise.

Authors:  Michael Horckmans; Elvira Léon-Gómez; Bernard Robaye; Jean-Luc Balligand; Jean-Marie Boeynaems; Chantal Dessy; Didier Communi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-08-03       Impact factor: 4.733

9.  SERCA2 Haploinsufficiency in a Mouse Model of Darier Disease Causes a Selective Predisposition to Heart Failure.

Authors:  Vikram Prasad; John N Lorenz; Valerie M Lasko; Michelle L Nieman; Wei Huang; Yigang Wang; David W Wieczorek; Gary E Shull
Journal:  Biomed Res Int       Date:  2015-05-03       Impact factor: 3.411

10.  P2Y6 receptor potentiates pro-inflammatory responses in macrophages and exhibits differential roles in atherosclerotic lesion development.

Authors:  Ricardo A Garcia; Mujing Yan; Debra Search; Rongan Zhang; Nancy L Carson; Carol S Ryan; Constance Smith-Monroy; Joanna Zheng; Jian Chen; Yan Kong; Huaping Tang; Samuel E Hellings; Judith Wardwell-Swanson; Joseph E Dinchuk; George C Psaltis; David A Gordon; Peter W Glunz; Peter S Gargalovic
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

View more
  7 in total

Review 1.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

2.  Synthesis and pharmacological characterization of multiply substituted 2H-chromene derivatives as P2Y6 receptor antagonists.

Authors:  Young-Hwan Jung; Qasim Shah; Sarah A Lewicki; Asmita Pramanik; Varun Gopinatth; Julie Pelletier; Jean Sévigny; Jamshed Iqbal; Kenneth A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2022-09-08       Impact factor: 2.940

3.  Purinergic dysregulation causes hypertensive glaucoma-like optic neuropathy.

Authors:  Youichi Shinozaki; Kenji Kashiwagi; Kazuhiko Namekata; Akiko Takeda; Nobuhiko Ohno; Bernard Robaye; Takayuki Harada; Takeshi Iwata; Schuichi Koizumi
Journal:  JCI Insight       Date:  2017-10-05

4.  Anti-proliferative Effects of Nucleotides on Gastric Cancer via a Novel P2Y6/SOCE/Ca2+/β-catenin Pathway.

Authors:  Hanxing Wan; Rui Xie; Jiangyu Xu; Jialin He; Bo Tang; Qingqing Liu; Sumin Wang; Yanjun Guo; Xin Yang; Tobias Xiao Dong; John M Carethers; Shiming Yang; Hui Dong
Journal:  Sci Rep       Date:  2017-05-26       Impact factor: 4.379

5.  Enhanced Keap1-Nrf2 signaling protects the myocardium from isoproterenol-induced pathological remodeling in mice.

Authors:  Gobinath Shanmugam; Anil Kumar Challa; Silvio H Litovsky; Asokan Devarajan; Ding Wang; Dean P Jones; Victor M Darley-Usmar; Namakkal Soorappan Rajasekaran
Journal:  Redox Biol       Date:  2019-05-04       Impact factor: 11.799

Review 6.  Purinergic Regulation of Endothelial Barrier Function.

Authors:  Muhammad Aslam; Dursun Gündüz; Christian Troidl; Jacqueline Heger; Christian W Hamm; Rainer Schulz
Journal:  Int J Mol Sci       Date:  2021-01-26       Impact factor: 5.923

7.  Modulation of P2Y6R expression exacerbates pressure overload-induced cardiac remodeling in mice.

Authors:  Kakeru Shimoda; Akiyuki Nishimura; Caroline Sunggip; Tomoya Ito; Kazuhiro Nishiyama; Yuri Kato; Tomohiro Tanaka; Hidetoshi Tozaki-Saitoh; Makoto Tsuda; Motohiro Nishida
Journal:  Sci Rep       Date:  2020-08-18       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.